IPG11406 / Immunophage Biotech - LARVOL DELTA

Phase IIa Study for IPG11406 in Patients With Lupus Nephritis (clinicaltrials.gov) - P1/2 | N=24 | Completed | Sponsor: Nanjing Immunophage Biotech Co., Ltd | Recruiting ➔ Completed | N=36 ➔ 24

Biomarker • Enrollment change • Trial completion • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Phase 1 Study for IPG11406 in Health Volunteer (clinicaltrials.gov) - P1 | N=66 | Completed | Sponsor: Nanjing Immunophage Biotech Co., Ltd | Recruiting ➔ Completed

Trial completion • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2) (clinicaltrials.gov) - P2 | N=144 | Not yet recruiting | Sponsor: Nanjing Immunophage Biotech Co., Ltd

New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Phase IIa Study for IPG11406 in Patients With Lupus Nephritis (clinicaltrials.gov) - P1/2 | N=36 | Recruiting | Sponsor: Nanjing Immunophage Biotech Co., Ltd | Trial primary completion date: Nov 2025 ➔ Apr 2026

Biomarker • Trial primary completion date • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Phase Ib/IIa Study for IPG11406 in Patients with Lupus Nephritis (clinicaltrials.gov) - P1/2 | N=36 | Recruiting | Sponsor: Nanjing Immunophage Biotech Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Phase Ib/IIa Study for IPG11406 in Patients with Lupus Nephritis (clinicaltrials.gov) - P1/2 | N=36 | Not yet recruiting | Sponsor: Nanjing Immunophage Biotech Co., Ltd

Biomarker • New P1/2 trial • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Phase 1 Study for IPG11406 in Health Volunteer (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: Nanjing Immunophage Biotech Co., Ltd | Trial completion date: Dec 2024 ➔ Apr 2025 | Trial primary completion date: Oct 2024 ➔ Feb 2025

Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Phase 1 Study for IPG11406 in Health Volunteer (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: Nanjing Immunophage Biotech Co., Ltd | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2024 ➔ Dec 2024 | Trial primary completion date: Jul 2024 ➔ Oct 2024

Enrollment open • Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Phase 1 Study for IPG11406 in Health Volunteer (clinicaltrials.gov) - P1 | N=66 | Not yet recruiting | Sponsor: Nanjing Immunophage Biotech Co., Ltd

New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease